Advertisement

Infection

pp 1–7 | Cite as

Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis

  • Tanaya BhowmickEmail author
  • Charles Liu
  • Brandon Imp
  • Ranita Sharma
  • Susan E. Boruchoff
Brief Report

Abstract

Introduction

Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major cause of morbidity and mortality in hospitalized patients. Ceftaroline fosamil (CPT) is the only available beta-lactam antibiotic with in vitro and in vivo activities against MRSA. There is currently limited clinical experience with CPT in complicated MRSA BSI.

Materials and Methods

We report a series of eight patients, including three whose strains had reduced susceptibility to vancomycin.

Results

CPT monotherapy was successfully used as salvage therapy for complicated MRSA BSI. The median time to documented clearance was 7 days.

Conclusion

Ceftaroline monotherapy is effective for clearance of refractory MRSA BSI related to implanted devices, endocarditis, and orthopedic infections.

Keywords

MRSA VISA Ceftaroline Endocarditis Bacteremia 

Notes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Liu C, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92.CrossRefGoogle Scholar
  2. 2.
    Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009;48:231–7.CrossRefGoogle Scholar
  3. 3.
    Charles PG, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–51.CrossRefGoogle Scholar
  4. 4.
    Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139–58.CrossRefGoogle Scholar
  5. 5.
    Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011;45:1384–98.CrossRefGoogle Scholar
  6. 6.
    Ho TT, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267–70.CrossRefGoogle Scholar
  7. 7.
    Lin JC, et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42–9.CrossRefGoogle Scholar
  8. 8.
    Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42:450–5.CrossRefGoogle Scholar
  9. 9.
    Sakoulas G, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317–33.CrossRefGoogle Scholar
  10. 10.
    Fabre V, et al. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1:046.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Allergy, Immunology and Infectious Diseases, Department of MedicineRutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Division of General Internal MedicineRutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations